Countries Europe
European Commission Approves First-in-Class Obicetrapib for LDL-C Reduction
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability...
September 25, 2026 | News
Bio-Techne Opens Düsseldorf Flagship Centre to Accelerate Life Sciences Innovation Across Europe
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and ...
September 24, 2026 | News
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...
September 23, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
Daiichi Sankyo, AstraZeneca’s Enhertu Wins EU Panel Backing for Early Breast Cancer
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vers...
September 21, 2026 | News
OGT Expands SureSeq NGS Indexing Capacity to 384 Samples per Run
OGT, a leading global provider of genomic research and diagnostic solutions, announced the expansion of its SureSeq™ Universal NGS Unique Dual Index ...
September 21, 2026 | News
Single Cell Discoveries Acquires TATAA Biocenter to Build Integrated Discovery-to-Validation CRO
Single Cell Discoveries (SCD), a specialist contract research organization (CRO) focused on discovery transcriptomics, has completed the acquisition of TAT...
September 16, 2026 | News
Bausch + Lomb Secures European CE Mark for Next-Generation SeeLyra Femtosecond Laser
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced European C...
September 14, 2026 | News
Celltrion Launches 300 mg Omlyclo Omalizumab Biosimilar Across Key European Markets
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by ye...
August 26, 2026 | News
SingHealth Launches Global Fellowship Network to Develop Future-Ready Healthcare Leaders
SingHealth is working alongside nine leading academic medical centres and health systems worldwide to formalise a structured exchange programme for healt...
August 14, 2026 | News
Fresenius Kabi's Vedolizumab Biosimilar Clears FDA and EMA Review Milestone
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intraveno...
August 04, 2026 | News
Polpharma Biologics' Vedolizumab Biosimilar Accepted for FDA and EMA Review
Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for r...
August 04, 2026 | News
IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand
IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharm...
August 03, 2026 | News
EU CHMP Backs Enhertu Plus Pertuzumab as First New First-Line HER2 Positive Metastatic Breast Cancer Treatment in Over a Decade
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by ...
July 28, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
